Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

The NKT cell ligand alpha-galactosylceramide suppresses allergic airway inflammation by induction of a Th1 response

: Knothe, Saskia; Mutschler, Vanessa; Rochlitzer, Sabine; Winkler, Carla; Ebensen, Thomas; Guzman, Carlos A.; Hohlfeld, Jens; Braun, A.; Muller, M.


Vaccine 29 (2011), No.25, pp.4249-4255
ISSN: 0264-410X
ISSN: 1873-2518
Journal Article
Fraunhofer ITEM ()
alpha-GalCerMPEG; invariant NKT cell; IFN-gamma

One experimental approach for the treatment of allergic reactions is the stimulation of immunoregulatory NKT cells with the synthetic glycolipid galactosylceramide. For a first evaluation of the immunomodulatory potential of GalCerMPEG a human in vitro allergy model was exploited. Acting as an adjuvant, the glycolipid induced an enhanced Th1-biased allergen-specific immune response of autologous lymphocytes. In a mouse model of allergic airway inflammation, GalCerMPEG-activated NKT cells promoted a cytokine environment in the spleen, leading to priming of Th1 cells. The shift towards a Th1-dominated allergen-specific immune response thus might mediate the abrogation of allergic airway inflammation and thereby might provide a valid option for therapeutic intervention.